BACKGROUND: There are several commercially available assays for the quantitation of HIV RNA. A new automated specimen preparation system, the Cobas AmpliPrep, was developed to automate this last part of the PCR. OBJECTIVES AND STUDY DESIGN: We compared the results obtained by the Roche Cobas Amplicor HIV-1 Monitor Ultrasensitive Test (MCA, manual sample preparation) with those by the Versant HIV-1 RNA 3.0 assay (bDNA). Secondly we compared the MCA with the new Cobas AmpliPrep/Cobas Amplicor HIV Monitor Ultrasensitive Test (CAP/CA, automated specimen preparation) by investigating clinical patient samples and a panel of HIV-1 non-B subtypes. Furthermore, we assessed the assay throughput and workflow (especially hands-on time) for all three assays. RESULTS: Seventy-two percent of the 140 investigated patient samples gave concordant results in the bDNA and MCA assays. The MCA values were regularly higher than the bDNA values. One sample was detected only by the MCA within the linear range of quantification. In contrast, 38 samples with results <50 copies/ml in the MCA showed in the bDNA results between 51 and 1644 copies/ml (mean value 74 copies/ml); 21 of these specimens were shown to have detectable HIV RNA < 50 copies/ml in the MCA assay. The overall agreement between the MCA and the CAP/CA was 94.3% (551/584). The quantification results showed significant correlation, although the CAP/CA generated values slightly lower than those generated by the manual procedure. We found that the CAP/CA produced comparable results with the MCA test in a panel of HIV-1 non-B subtypes. CONCLUSIONS: All three assays showed comparable results. The bDNA provides a high sample throughput without the need of full automation. The new CAP/CA provides reliable test results with no HIV-subtype specific influence and releases time for other works in the laboratory; thus it is suitable for routine diagnostic PCR.
BACKGROUND: There are several commercially available assays for the quantitation of HIV RNA. A new automated specimen preparation system, the Cobas AmpliPrep, was developed to automate this last part of the PCR. OBJECTIVES AND STUDY DESIGN: We compared the results obtained by the Roche Cobas Amplicor HIV-1 Monitor Ultrasensitive Test (MCA, manual sample preparation) with those by the Versant HIV-1 RNA 3.0 assay (bDNA). Secondly we compared the MCA with the new Cobas AmpliPrep/Cobas Amplicor HIV Monitor Ultrasensitive Test (CAP/CA, automated specimen preparation) by investigating clinical patient samples and a panel of HIV-1 non-B subtypes. Furthermore, we assessed the assay throughput and workflow (especially hands-on time) for all three assays. RESULTS: Seventy-two percent of the 140 investigated patient samples gave concordant results in the bDNA and MCA assays. The MCA values were regularly higher than the bDNA values. One sample was detected only by the MCA within the linear range of quantification. In contrast, 38 samples with results <50 copies/ml in the MCA showed in the bDNA results between 51 and 1644 copies/ml (mean value 74 copies/ml); 21 of these specimens were shown to have detectable HIV RNA < 50 copies/ml in the MCA assay. The overall agreement between the MCA and the CAP/CA was 94.3% (551/584). The quantification results showed significant correlation, although the CAP/CA generated values slightly lower than those generated by the manual procedure. We found that the CAP/CA produced comparable results with the MCA test in a panel of HIV-1 non-B subtypes. CONCLUSIONS: All three assays showed comparable results. The bDNA provides a high sample throughput without the need of full automation. The new CAP/CA provides reliable test results with no HIV-subtype specific influence and releases time for other works in the laboratory; thus it is suitable for routine diagnostic PCR.
Authors: Jeffrey J Germer; Jordan L Bendel; Craig A Dolenc; Sarah R Nelson; Amanda L Masters; Tara M Gerads; Jayawant N Mandrekar; P Shawn Mitchell; Joseph D C Yao Journal: J Clin Microbiol Date: 2007-07-18 Impact factor: 5.948
Authors: Pablo S Rivadeneira; Claude H Moog; Guy-Bart Stan; Cecile Brunet; François Raffi; Virginie Ferré; Vicente Costanza; Marie J Mhawej; Federico Biafore; Djomangan A Ouattara; Damien Ernst; Raphael Fonteneau; Xiaohua Xia Journal: Biores Open Access Date: 2014-10-01
Authors: Jane Greig; Philipp du Cros; Derryck Klarkowski; Clair Mills; Steffen Jørgensen; P Richard Harrigan; Daniel P O'Brien Journal: J Int AIDS Soc Date: 2011-05-12 Impact factor: 5.396
Authors: Olufemi S Amoo; Idowu A Taiwo; Olumuyiwa O Salu; Azuka P Okwuraiwe; Chika K Onwuamah; Morenike A Awe; Osaga O Oforomeh; Daniel I Onwujekwe; Oliver C Ezechi; Audu R Ajuma Journal: Afr J Lab Med Date: 2013-05-15
Authors: Luuk Gras; Suzanne Jurriaans; Margreet Bakker; Ard van Sighem; Daniela Bezemer; Christophe Fraser; Joep Lange; Jan M Prins; Ben Berkhout; Frank de Wolf Journal: PLoS One Date: 2009-10-07 Impact factor: 3.240